Platelet aggregation pathway network-based approach for evaluating compounds efficacy.

Area of Science:

• Pharmacology
• Computational Chemistry
• Systems Biology

Background:

• Traditional Chinese Medicines (TCMs) possess numerous compounds with diverse biological activities.
• Existing drug screening methods often focus on single targets, potentially overlooking complex molecular interactions.
• Platelet aggregation is a critical factor in thrombotic diseases, necessitating effective antiplatelet therapies.

Purpose of the Study:

• To develop and validate a network-based model for screening potential antiplatelet aggregation compounds.
• To assess the efficacy of network efficiency and network flux models in predicting drug activity compared to traditional methods.
• To identify promising bioactive molecules from TCMs for antiplatelet aggregation therapy.

Main Methods:

• Utilized multitarget docking and network analysis focused on the platelet aggregation pathway.
• Developed and applied network efficiency and network flux models for molecular screening.
• Validated model predictions against experimental results for known TCM compounds and predicted nonglycoside compounds.

Main Results:

• The network efficiency and network flux model demonstrated strong agreement with experimental antiplatelet aggregation activities.
• Correlation coefficients of 0.73 and 0.90 were achieved for TCM active ingredients and predicted nonglycoside compounds, respectively.
• The model successfully identified potential bioactive compounds with antiplatelet aggregation potential.

Conclusions:

• Network efficiency and network flux models offer a more comprehensive approach to drug screening than single-target methods.
• These computational models can effectively evaluate potential bioactive compounds from TCMs.
• The proposed model bridges the gap between computational predictions and clinical indicators for antiplatelet drug development.